Bocep market share goal?

Quote
Ideally we get approved with both Pegs and so we can get a bigger share than just 25%. Tel if approved with just one peg will be limited...and hopefully the co pay coupons will help.
 






Anonymous said:
Ideally we get approved with both Pegs and so we can get a bigger share than just 25%. Tel if approved with just one peg will be limited...and hopefully the co pay coupons will help.
Click to expand...

Originally, this compound was viewed as a means to re-invigorate the PegIntron line because the cost of boceprevir alone was pretty high. Hpwever, there seems to be nothing that would require pairing boceprevir with PegIntron and telaprevir with Pegasys. Just as well since the market share presently seems to prefer Pegasys by a bit. The first marketing task is to invigorate the HCV patient population. Vertex is already doing that in the mainstream media and thereby getting some association with therapy without yet really pushing telaprevir per se. It will be intersting to see how the pricing gets worked out. Approval in EU may be swift but setting the price in each country might take some time.
 






Anonymous said:
Ideally we get approved with both Pegs and so we can get a bigger share than just 25%. Tel if approved with just one peg will be limited...and hopefully the co pay coupons will help.
Click to expand...

If anything, both PI's get approved with both pegs. If Tel is approved with Pegasys, how the hell do you say they're limited?!? Pegasys has a 82% market share right now and I think they'll get all the Tel patients. I also think people will use PegIntron with Tel too. I hate to say it...but the KOL's are doing a better job selling ME on Tel use than Merck is selling me on Bocep. Kinda sucks! Sorry Brian Williams....the report was lame...I guess Merck didn't pay enough to make it more in depth and interesting.
 






Vertex is hiring a lot of talented reps and a HUGE amount of Home Office people. I'm surprised they didn't take a partner to help them sell in the U.S (JNJ paid for development and will be promoting it in the rest of the world I believe). Launching a new drug is extremely complex. They'll have some bumps in the road in the early going.

I expect Bocep to achieve 35% market share in the early going. Either way, I'd like to be a rep for either product.
 






Top Bottom
Back
Quote